Evidence map›Paper›PMID 41744903›Full record

ArticleAntibodies (Basel, Switzerland)2026

Microsecond Dynamics of Fc-CD16a Recognition: Impact of Mutations, Core Fucosylation, and Fc Asymmetry.

Sébastien Estaran, Bernard Hehlen, Alain Chavanieu

Abstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sébastien EstaranInstitut des Biomolécules Max Mousseron (IBMM), Université de Montpellier, CNRS, École Nationale Supérieure de Chimie de Montpellier (ENSCM), 34090 Montpellier, France.ORCID 0009-0008-2901-5464
Bernard HehlenLaboratoire Charles Coulomb, UMR 5221, CNRS, Université de Montpellier, 34095 Montpellier, France.
Alain ChavanieuInstitut des Biomolécules Max Mousseron (IBMM), Université de Montpellier, CNRS, École Nationale Supérieure de Chimie de Montpellier (ENSCM), 34090 Montpellier, France.ORCID 0000-0002-0512-5115

Funding

Agence Nationale de la Recherche ANR-23-IAHU-0009Immun4Cure France 2030 /ANR-23-IAHU-0009).Immun4Cure University Hospital Institute "Institute for innovative immunotherapies in autoimmune diseases" (France 2030 /ANR-23-IAHU-0009).
6 · The paper itself

Abstract

BACKGROUND/

objectivesAntibody-dependent cellular cytotoxicity relies on the interaction between the Fc region of immunoglobulin G1 (IgG1) and the CD16a receptor. While removal of core fucosylation on Fc and introduction of the DFTE mutation set (S239D, H268F, S324T, I332E) are known to enhance CD16a binding, the detailed contributions of these engineered sites in solution remain incompletely defined.

methodsHere, we employed 1 µs molecular dynamics simulations to map, at atomic resolution, the interaction networks stabilizing pre-formed Fc-CD16a complexes, including afucosylated Fc-wild-type, DFTE-engineered, Fc-fucosylated, and asymmetrically engineered Fc variants.

resultsOur results show that only S239D, present on both Fc chains, and H268F on chain A consistently contribute to stabilizing the CD16a interface, while I332E does not form persistent interactions. Glycan-protein contacts are primarily intrachain, with transient interchain glycan-glycan interactions not contributing significantly to complex stability. Fucosylation on Fc significantly reduces binding stability by disrupting peripheral interactions and critical glycan-mediated contacts. Notably, the asymmetric Fc variant, in which the two heavy chains carry distinct sets of substitutions, retains high-affinity binding despite lacking S239D and carrying core fucose, through a novel hydrophobic cluster and reinforced peripheral electrostatic interactions.

conclusionsAltogether, these findings provide a quantitative framework for how targeted mutations and fucose modifications remodel Fc-CD16a interactions, offering insights for the rational design of next-generation therapeutic antibodies.

Indexed as

antibody-dependent cellular cytotoxicity (ADCC)DFTE mutationsFc-FcγRIIIa interactionfucosylationmolecular dynamics simulationnon-covalent interactionsprotein–glycan interaction

Identifiers

PMID41744903
PMCPMC12937375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.